{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:53:02Z","timestamp":1794639182440,"version":"4.9.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.ygyno.2009.03.004","type":"journal-article","created":{"date-parts":[[2009,4,7]],"date-time":"2009-04-07T08:49:06Z","timestamp":1239094146000},"page":"335-340","source":"Crossref","is-referenced-by-count":55,"title":["Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: A pilot study"],"prefix":"10.1016","volume":"113","author":[{"given":"A.","family":"Fagotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Grimolizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fanfani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Vizzielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Naldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5 Suppl 12","key":"10.1016\/j.ygyno.2009.03.004_bib1","first-page":"40","article-title":"Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III\/IV ovarian cancer (from the Gynecologic Oncology Group)","volume":"23","author":"McGuire","year":"1996","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.004_bib2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J. Clin Oncol."},{"key":"10.1016\/j.ygyno.2009.03.004_bib3","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin Oncol."},{"key":"10.1016\/j.ygyno.2009.03.004_bib4","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.1992.10.5.706","article-title":"Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer","volume":"10","author":"Alberts","year":"1992","journal-title":"J. Clin Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2009.03.004_bib5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11912-005-0010-4","article-title":"Secondary cytoreduction for patients with recurrent ovarian cancer","volume":"7","author":"D\u00edaz-Montes","year":"2005","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2009.03.004_bib6","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J. Clin Oncol."},{"key":"10.1016\/j.ygyno.2009.03.004_bib7","first-page":"4081","article-title":"Intraperitoneal hyperthermic treatment of implanted peritoneal cancer in rats","volume":"40","author":"Shiu","year":"1980","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2009.03.004_bib8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF02172661","article-title":"Hyperthermia in cancer growth regulation","volume":"4","author":"Vernon","year":"1992","journal-title":"Biotherapy"},{"key":"10.1016\/j.ygyno.2009.03.004_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/09553009414551121","article-title":"Effect of hyperthermia on the number of platinum atoms binding to DNA of HeLa cells treated with 195mPt-radiolabelled cis-diaminedichloroplatinum (II)","volume":"66","author":"Akaboshi","year":"1994","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.ygyno.2009.03.004_bib10","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/(SICI)1097-0142(19970301)79:5<884::AID-CNCR3>3.0.CO;2-C","article-title":"Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery","volume":"79","author":"Fujimoto","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2009.03.004_bib11","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1177\/000313480106701019","article-title":"Prospective trial for the treatment of malignant peritoneal mesothelioma","volume":"67","author":"Loggie","year":"2001","journal-title":"Am. Surg."},{"key":"10.1016\/j.ygyno.2009.03.004_bib12","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10434-999-0727-7","article-title":"Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy","volume":"6","author":"Sugarbaker","year":"1999","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.004_bib13","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0959-8049(01)00058-2","article-title":"Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin","volume":"37","author":"Witkamp","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2009.03.004_bib14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/030089160108700302","article-title":"Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study","volume":"7","author":"Deraco","year":"2001","journal-title":"Tumori"},{"key":"10.1016\/j.ygyno.2009.03.004_bib15","first-page":"1329","article-title":"Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy","volume":"22","author":"Panteix","year":"2002","journal-title":"Anticancer Res."},{"issue":"Suppl 1","key":"10.1016\/j.ygyno.2009.03.004_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/ijgc-00009577-200409001-00601","article-title":"Secondary surgical cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent ovarian and endometrial cancer","volume":"14","author":"Helm","year":"2004","journal-title":"Int. Gynecol. Cancer Soc."},{"issue":"2","key":"10.1016\/j.ygyno.2009.03.004_bib17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/annonc\/mdf018","article-title":"Multicentre phase II study of oxaliplatin as a single agent in cisplatin\/carboplatin +\/\u2212 taxane-pretreated ovarian cancer patients","volume":"13","author":"Dieras","year":"2002","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2009.03.004_bib18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00000421-200012000-00007","article-title":"Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced\/recurrent ovarian cancer","volume":"23","author":"Delaloge","year":"2000","journal-title":"Am. J. Clin Oncol."},{"key":"10.1016\/j.ygyno.2009.03.004_bib19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdf019","article-title":"Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution","volume":"13","author":"Elias","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.004_bib20","first-page":"303","article-title":"HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin","volume":"134","author":"Elias","year":"2007","journal-title":"Cancer Treat res."},{"issue":"22","key":"10.1016\/j.ygyno.2009.03.004_bib21","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2009.03.004_bib22","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/annonc\/mdm136","article-title":"Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study","volume":"18","author":"Ferrandina","year":"2007","journal-title":"Ann. Oncol."},{"issue":"3\u20134","key":"10.1016\/j.ygyno.2009.03.004_bib23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000159266","article-title":"A treatment selection protocol for recurrent ovarian cancer patients: the role of fdg-pet\/ct and staging laparoscopy","volume":"75","author":"Fagotti","year":"2008","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2009.03.004_bib24","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/annonc\/mdm137","article-title":"Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer","volume":"18","author":"Bijelic","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.004_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jso.21057","article-title":"Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy","volume":"98","author":"Younan","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.004_bib26","unstructured":"National Cancer Institute. Cancer Therapy Evaluation Program: Common Toxicity Criteria. Version 2.0 1999; http:\/\/ctep.info.nih.gov (20 April 1999, date last accessed)."},{"key":"10.1016\/j.ygyno.2009.03.004_bib27","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1200\/JCO.2002.07.177","article-title":"Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology","volume":"10","author":"Rizzo","year":"2002","journal-title":"J. Clin Oncol."},{"key":"10.1016\/j.ygyno.2009.03.004_bib28","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.ejca.2006.03.025","article-title":"Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations","volume":"42","author":"Ferrandina","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2009.03.004_bib29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"Natl. Cancer Inst"},{"key":"10.1016\/j.ygyno.2009.03.004_bib30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jso.21068","article-title":"The intraoperative staging systems in the management of peritoneal surface malignancy","volume":"98","author":"Portilla","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.004_bib31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jso.21083","article-title":"Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer","volume":"98","author":"Helm","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.004_bib32","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.004_bib33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.004_bib34","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1056\/NEJMoa041125","article-title":"Secondary surgical cytoreduction for advanced ovarian carcinoma","volume":"351","author":"Rose","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2009.03.004_bib35","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/sj.bjc.6602466","article-title":"Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection","volume":"92","author":"Onda","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2009.03.004_bib36","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1245\/s10434-007-9648-5","article-title":"Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis","volume":"15","author":"Ceelen","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2009.03.004_bib37","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J. Clin Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809001401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809001401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T21:47:22Z","timestamp":1739051242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809001401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0090825809001401"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.03.004","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}